Program
palbociclib
Also written as “Palbociclib”, “PD-0332991” and “Palbociclib 125mg”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Renal Cell · Sarcoma, Ewing · Squamous Cell Carcinoma of Head and Neck · COVID-19, led by 7 companies.
Drug pagePalbociclib: every studyMany companies study it; this page follows only the 35 they lead. All 225 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 291 open or running | phase 4since Jan 22, 2016 | Aug 30, 2005 | Dec 31, 2029phase 2 · NCT05226871 |
| biotx.aiits history only | 10 open or running | phase 2since Apr 26, 2022 | Apr 26, 2022 | none ahead |
| Criteriumits history only | 11 open or running | phase 2since Sep 3, 2020 | Sep 3, 2020 | Dec 31, 2027phase 2 · NCT04567420 |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 1since Apr 16, 2025 | Apr 16, 2025 | Oct 2027phase 1 · NCT06941142 |
| iOMEDICOits history only | 10 open or running | phase 2since Aug 25, 2016 | Aug 25, 2016 | none ahead |
| Megalabsits history only | 10 open or running | phase 4since Mar 19, 2024 | Mar 19, 2024 | none ahead |
| Merckits history only | 11 open or running | phase 2since Jul 18, 2022 | Jul 18, 2022 | Dec 22, 2026phase 2 · NCT05468697 |
Also a collaborator on its studies: AstraZeneca and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since Aug 30, 2005.
- Jan 6, 2015Phase 1 study in Hepatic InsufficiencyPfizer · NCT02334800 · 28 enrolled · United States
- Jul 13, 20152 phase 1 studiesPfizer · NCT02499146, NCT02501902
- Jul 13, 2015Phase 2 study in Squamous Cell Carcinoma of Head and NeckPfizer · NCT02499120 · 125 enrolled · United States, Czechia, Hungary and more
- Nov 6, 2015Phase 3 study in Breast NeoplasmsPfizer · NCT02600923 · 131 enrolled · Argentina, Brazil, Colombia and more
- Jan 22, 2016Phase 4 study in Breast NeoplasmsPfizer · NCT02679755 · 252 enrolled · Australia, India
- Aug 25, 2016iOMEDICO’s first study: phase 2 study in Breast NeoplasmsNew to iOMEDICOiOMEDICO · NCT02894398 · 388 enrolled · Germany
- Jun 16, 2017Phase 1 study in Healthy VolunteerPfizer · NCT03220191 · 12 enrolled · United States
- Oct 9, 2018Phase 2 study in Sarcoma, EwingPfizer · NCT03709680 · 128 enrolled · United States, Brazil, Canada and more
- Sep 3, 2020Criterium’s first study: phase 2 study in Breast NeoplasmsNew to CriteriumCriterium · NCT04567420 · 70 enrolled · United States
- Jan 26, 2022Phase 2 study in Breast NeoplasmsPfizer · NCT05226871 · 35 enrolled · United States, China, Mexico and more
- Apr 26, 2022biotx.ai’s first study: phase 2 study in COVID-19New to biotx.aibiotx.ai · NCT05371275 · Germany
- Jul 18, 2022Merck’s first study: phase 2 study in Carcinoma, Renal CellNew to MerckMerck · NCT05468697 · 60 enrolled · United States, Australia, Israel
- Mar 19, 2024Megalabs’ first study: phase 4 study in BioequivalenceNew to MegalabsMegalabs · NCT06331715 · 24 enrolled · India
- Apr 16, 2025CSPC Pharmaceutical Group’s first study: phase 1 study in Advanced Breast CancerNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06941142 · 382 planned
Ahead
- Dec 22, 2026Primary completion: phase 2 study in Carcinoma, Renal CellMerck · NCT05468697
- Oct 2027Primary completion: phase 1 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT06941142
- Dec 31, 2027Primary completion: phase 2 study in Breast NeoplasmsCriterium · NCT04567420
- Dec 31, 2029Primary completion: phase 2 study in Breast NeoplasmsPfizer · NCT05226871
TargetBeta
“CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor”ChEMBL 37, by rule
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06941142Advanced Breast Cancer | 1 | Not yet recruiting | CSPC Pharmaceutical Group | Oct 2027 | 382 |
| NCT06331715Bioequivalence · India | 4 | Completed | Megalabs | Apr 1, 2024 | 24 |
| NCT05468697Carcinoma, Renal Cell · United States, Australia, Israel | 2 | Active, not recruiting | Merck | Dec 22, 2026 | 60 |
| NCT05371275COVID-19 · Germany | 2 | Withdrawn | biotx.ai | Oct 2022 | 0 |
| NCT05226871Breast Neoplasms · United States, China, Mexico and more | 2 | Active, not recruiting | Pfizer | Dec 31, 2029 | 35 |
| NCT04567420Breast Neoplasms · United States | 2 | Active, not recruiting | Criterium | Dec 31, 2027 | 70 |
| NCT03709680Sarcoma, Ewing · United States, Brazil, Canada and more | 2 | Completed | Pfizer | Aug 26, 2024 | 128 |
| NCT03220191Healthy Volunteer · United States | 1 | Completed | Pfizer | Sep 3, 2017 | 12 |
| NCT02894398Breast Neoplasms · Germany | 2 | Completed | iOMEDICO | Feb 15, 2023 | 388 |
| NCT02679755Breast Neoplasms · Australia, India | 4 | Completed | Pfizer | Jul 25, 2019 | 252 |
| NCT02600923Breast Neoplasms · Argentina, Brazil, Colombia and more | 3 | Completed | Pfizer | May 28, 2019 | 131 |
| NCT02501902Metastatic Pancreatic Ductal Adenocarcinoma · United States, Spain | 1 | Completed | Pfizer | Oct 10, 2018 | 76 |
| NCT02499146Advanced Breast Cancer · China | 1 | Completed | Pfizer | Jul 31, 2018 | 26 |
| NCT02499120Squamous Cell Carcinoma of Head and Neck · United States, Czechia, Hungary and more | 2 | Completed | Pfizer | Jul 19, 2018 | 125 |
| NCT02334800Hepatic Insufficiency · United States | 1 | Completed | Pfizer | Oct 9, 2016 | 28 |
| NCT02311946Healthy · United States | 1 | Completed | Pfizer | Apr 2015 | 60 |
| NCT02297438Breast Neoplasms · China, Hong Kong, Singapore and more | 3 | Completed | Pfizer | Aug 31, 2020 | 340 |
| NCT02222441Healthy · United States | 1 | Completed | Pfizer | Dec 2014 | 14 |
| NCT02131298Healthy · United States | 1 | Completed | Pfizer | Jun 2014 | 12 |
| NCT02085538Renal Insufficiency · United States | 1 | Completed | Pfizer | May 2016 | 31 |
| NCT02059330Healthy · United States | 1 | Completed | Pfizer | Jun 2014 | 27 |
| NCT01953731Healthy · United States | 1 | Completed | Pfizer | Jan 2014 | 15 |
| NCT01942135Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Pfizer | Dec 5, 2014 | 521 |
| NCT01918176Healthy · United States | 1 | Completed | Pfizer | Dec 2013 | 26 |
| NCT01906125Healthy · United States | 1 | Completed | Pfizer | Jan 2014 | 73 |
| NCT01821066Healthy · United States | 1 | Completed | Pfizer | Aug 2013 | 25 |
| NCT01802476Healthy · United Kingdom | 1 | Completed | Pfizer | Jun 2013 | 14 |
| NCT01756781Healthy · United States | 1 | Completed | Pfizer | Jul 2013 | 26 |
| NCT01740427Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Pfizer | Feb 26, 2016 | 666 |
| NCT01684215Neoplasms · Japan | 2 | Completed | Pfizer | Mar 4, 2016 | 61 |
| NCT01602887Breast Neoplasms · United States | 1 | Completed | Pfizer | Nov 2012 | 24 |
| NCT00721409Breast Neoplasms · United States, Canada, France and more | 2 | Completed | Pfizer | Nov 29, 2013 | 177 |
| NCT00555906Multiple Myeloma · United States, Czech Republic, Germany | 2 | Completed | Pfizer | Aug 2012 | 53 |
| NCT00420056Lymphoma, Mantle-Cell · United States | 1 | Completed | Pfizer | Mar 2010 | 17 |
| NCT00141297Neoplasms · United States | 1 | Completed | Pfizer | Jul 2008 | 74 |
How it is read
Names in the registry
- “Palbociclib”, 16 entries
- “PD-0332991”, 12 entries
- “palbociclib”, 5 entries
- “Palbociclib 125mg”, 3 entries
- “Palbociclib alone”, 3 entries
Codes read as this program: PD0332991.
Conditions, from the studies’ own filings
- Breast Neoplasms, 13 studies
- Carcinoma, Renal Cell, 1 study
- Sarcoma, Ewing, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.